Chemotherapy continuity and incidence of febrile neutropenia with CHOP therapy in an outpatient setting

Abstract

Abstract. The cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) regimen is considered to be a standard treatment for non-Hodgkin's lymphoma (NHL). Patients receiving CHOP chemotherapy often experience febrile neutropenia (FN) due to myelotoxicity. The proper management of FN is essential to guarantee a positive outcome of the NHL treatment. Therefore, the present study retrospectively examined chemotherapy continuity and the incidence of FN during CHOP therapy in an outpatient setting. The subjects were 136 patients who received CHOP chemotherapy between January 2012 and December 2014. A total of 31 patients unable to be treated in an outpatient setting were excluded from the study. Of the remaining 105 patients, 73 patients who did not require hospitalization during the chemotherapy treatment were included in the non-hospitalized group, and 32 patients who required hospitalization during chemotherapy treatment were included in the re-hospitalization group. The numbers of patients from these two groups who completed the planned treatment were 71 and 24, respectively (P<0.01). In addition, the duration of granulocyte-colony stimulating factor (G-CSF) treatment was 5.3±1.22 and 6.1±1.46 days, respectively (P<0.01). The numbers of patients experiencing FN in an outpatient setting were 14 and 19, respectively (P<0.01). During administration of primary prophylaxis with G-CSF, the incidence of FN was 21.0% (22/105) in cycle 1. In conclusion, the present study has revealed a requirement to educate patients about infection prevention prior to the first cycle of chemotherapy. Patients who require the administration of long-term G-CSF are at risk of unplanned re-hospitalization, and treating them with polyethylene glycol G-CSF to reduce the number of required injections should be considered as an option. Therefore, proper supportive therapy and management of infection are important to safely treat patients with CHOP in an outpatient setting.

Hematologic Toxicities of Chemotherapy in Lung Cancer Patients: A Retrospective Study in Dr. M. Djamil Hospital Padang, Indonesia

“…Hematologic toxicities from chemotherapy may generally occur from the first to eighteenth week and most commonly arise in the fifth week or at the end of the second cycle. 29,30 The present study found that hematologic toxicities progressed at the end of the second cycle of chemotherapy, where the grade 3 toxicity increased dramatically from 0 to 37.50%. This might occur because the chemotherapy drugs, in addition to destroying the cancer cells, also kill progenitor cells that produce granulocytes, erythrocytes, and platelets in peripheral blood circulation.…”

Hematological Side Effects Management of Paclitaxel - Carboplatin Chemotherapy in Lung Cancer

“…Toxicity events often appear in the fifth week or at the end of the second cycle. 16 Cycles of chemotherapy are reported to be directly proportional to the severity of toxicity. A more significant number of chemotherapy cycles, the patient experience more severe toxicity.…”

The effect of vitamin C supplementation on neutropenia induced by cyclophosphamide in mice

“…The adverse effects caused by the administration of antineoplastic drugs usually develop after the first cycle of chemotherapy, as a consequence of the high doses administered. There is a cumulative effect that remains throughout the treatment, which can lead to weight loss and increased vulnerability to potential infections 4,5,6 .…”